natgillin/translations-raw huggingface dataset:
The full EPAR for Zulvac SBV can be found on the Agency’s website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila Zulvac SBV je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
The full EPAR for Zutectra can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Zutectra je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR for Zyclara can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Zyclara je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR for Zycortal can be found on the Agency’s website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila za zdravilo Zycortal je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
The full EPAR for Zydelig can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR)za zdravilo Zydelig je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR for Zykadia can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Zykadia je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR for Zypadhera can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Zypadhera je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR for Zyprexa can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Zyprexa je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR for Zyprexa Velotab can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Zyprexa Velotab je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR for Zytiga can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Zytiga je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The full EPAR summary for Xigduo can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celoten povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Xigduo je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPARs for the reference medicines can also be found on the Agency’s website.
Celotni evropski javni poročili o oceni zdravila (EPAR) za referenčni zdravili sta na voljo na spletni strani agencije.
The full EPARs for the reference medicines can also be found on the EMEA’s website.
Celotno evropsko javno poročilo o oceni zdravila za referenčni zdravili je na voljo na spletni strani agencije EMEA.
The full list of bacteria against which Altargo is active can be found in the Summary of Product Characteristics.
Celoten seznam bakterij, proti katerim je zdravilo Altargo učinkovito, najdete v Povzetku glavnih značilnosti zdravila.
The full list of bacteria against which Ketek is active can be found in the summary of product characteristics (also part of the EPAR).
Celoten seznam bakterij, proti katerim je zdravilo Ketek učinkovito, je na voljo v povzetku glavnih značilnosti zdravila (ki je prav tako del EPAR).
The full list of bacteria against which Zinforo is active can be found in the summary of product characteristics (also part of the EPAR).
Za celoten seznam bakterij, proti katerim učinkuje zdravilo Zinforo, glejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
The full list of roundworms and coccidia against which Procox is effective can be found in the summary of product characteristics (SPC).
Za celoten seznam valjastih črvov in kokcidij, proti katerim deluje zdravilo Procox, glejte povzetek glavnih značilnosti zdravila (SPC).
The full name of your medicine is CellCept 1 g/5 ml powder for oral suspension.
Celotno ime zdravila je CellCept 1 g/5 ml prašek za peroralno suspenzijo.
The full name of your medicine is CellCept 250 mg capsules.
Celotno ime zdravila je CellCept 250 mg kapsule.
The full name of your medicine is CellCept 500 mg film-coated tablets.
Celotno ime zdravila je CellCept 500 mg filmsko obložene tablete.
The full name of your medicine is CellCept 500 mg powder for concentrate for solution for infusion.
Celotno ime zdravila je CellCept 500 mg prašek za koncentrat za raztopino za infundiranje.
The fully reconstituted product will appear clear and may have a few small bubbles or foam around the edge of the vial.
Pripravljena raztopina je videti bistra, ob robu viale pa lahko ostanejo majhni mehurčki ali pena.
The functioning of your thyroid gland will be checked regularly or whenever thought necessary by your doctor for other reasons.
Delovanje vaše ščitnice bo redno kontrolirano ali kadar bo zdravnik mislil, da je to potrebno zaradi drugih razlogov.
The functioning of your thyroid gland will be checked regularly or whenever thought necessary by your doctor for other reasons.
Delovanje ščitnice je treba preverjati redno ali tudi dodatno zaradi drugih razlogov, če tako oceni zdravnik.
The fundamental requirement of the treatment of periodontal disease is mechanical and/or surgical intervention by the veterinarian.
Osnovni pogoj pri zdravljenju periodontalnega obolenja je veterinarski, mehanični in/ali kirurški poseg.
The fusion protein consists of prostatic acid phosphatase (PAP), a molecule found in most prostate cancer cells, attached to granulocyte-macrophage colony-stimulating factor (GM-CSF), a molecule that activates immune cells.
Fuzijsko beljakovino sestavlja prostatična kisla fosfataza (PAP – prostatic acid phosphatase), tj. molekula, ki jo najdemo v večini celic raka prostate in je vezana na granulocitne makrofagne kolonije spodbujajoči faktor (GM-CSF – granulocyte- macrophage colony-stimulating factor), tj. molekulo, ki aktivira imunske celice.
The FVIII:C of Kovaltry can be measured in plasma with a one-stage coagulation assay as well as with a chromogenic assay using the routine methods of the laboratory.
Vrednost FVIII:C zdravila Kovaltry se lahko izmeri v plazmi tako z enostopenjskim koagulacijskim preizkusom kot s kromogenim preizkusom z uporabo rutinskih laboratorijskih metod.
The gas cylinder should be put in an equipped site with appropriate material in order to hold the gas cylinder vertically.
Jeklenko morate namestiti v prostor, opremljen z ustreznimi materiali, ki omogočajo, da je jeklenka postavljena pokončno.
the gas cylinders should be fixedly stowed away in order to avoid untimely fall
jeklenke morajo biti pritrjene, da preprečite padce
The gas is removed naturally from the body through the lungs.
Plin se iz telesa izloči na naraven način skozi pljuča.
The gastro-resistant tablets are yellow, oval, biconvex film-coated tablets imprinted with “P20” on one side.
Gastrorezistentne tablete so rumene, ovalne, obojestransko izbočene filmsko obložene tablete z oznako “P20” na eni strani.
The gE- (glycoprotein E negative) characteristic of the vaccine virus makes it possible to distinguish between antibodies induced by vaccination with this product and those induced by field infection with Aujeszky’s disease virus, if the vaccine is used in association with an appropriate diagnostic test.
gE- (Glikoprotein E negativen) je značilen za cepivo in se odlikuje ravno v tem, da omogoča s specifičnim diagnostičnim testom potrditev prisotnosti protiteles, nastalih zaradi cepljenja in izključitev protiteles, pridobljenih z okužbo virusov Aujeszkyjeve bolezni iz okolja.
The gel is allowed to dry for approximately 10 minutes before placing a light-tight dressing over the treatment site.
Počakajte, da se gel suši okoli 10 minut, in nato na mesto zdravljenja namestite povoj, ki ne prepušča svetlobe.
The gel should be allowed to dry for approximately 10 minutes, before an occlusive light-tight dressing is placed over the treatment site.
Gel naj se suši približnos 10 minut, nato pa se na mesto zdravljenja namesti okluzivni povoj, ki ne prepušča svetlobe.
The gel should be prepared at the patient’s bedside.
Gel morate pripraviti ob bolnikovi postelji.
The gel should cover the lesions or entire fields and approximately 5 mm of the surrounding area with a film of about 1 mm thickness.
Lezije ali celotna polja in približno 5 mm okoliškega območja je treba premazati z gelom v debelini okoli 1 mm.
The gelatin sponges should be handled and used according to the manufacturer’s instructions in the package insert that accompanies the gelatin sponge.
Želatinske gobice je treba uporabljati v skladu z navodilom za uporabo proizvajalca, ki je priloženo želatinski gobici.
The GEMINI II Study was a randomised, double-blind, placebo-controlled study evaluating efficacy endpoints at Week 6 and Week 52.
Študija GEMINI II je bila randomizirana, dvojno slepa, s placebom nadzorovana študija, ki je vrednotila opazovane dogodke učinkovitosti v 6. tednu in 52. tednu.
The GEMINI III Study was a second randomised, double-blind, placebo-controlled study that evaluated efficacy at Week 6 and Week 10 in the subgroup of patients defined as having failed at least one conventional therapy and failed TNF antagonist therapy (including primary non-responders) as well as the overall population, which also included patients who failed at least one conventional therapy and were naïve to TNF antagonist therapy.
Študija GEMINI III je bila druga randomizirana, dvojno slepa, s placebom nadzorovana študija, ki je vrednotila učinkovitost v 6. tednu in 10. tednu v podskupini bolnikov, ki se niso odzvali vsaj na eno ustaljeno zdravljenje in na zdravljenje z zaviralcem TNFα (vključno s primarnim neodzivom) pa tudi v celotni populaciji, ki je prav tako vključevala bolnike, ki se niso odzvali na vsaj eno ustaljeno zdravljenje in se predhodno še niso zdravili z zaviralcem TNFα.
The general safety profile of either administration routes were comparable, although injection-site reactions were less frequent in the IM group (15.8%) compared with the SC group (25.8%).
Splošni profil varnosti po obeh načinih injiciranja je bil primerljiv, čeprav so bile reakcije na mestu vboda manj pogoste pri i.m. uporabi (15,8 %) v primerjavi s s.c. uporabo (25,8 %).
The general safety profiles of the IM and SC administration routes were comparable; however, fewer subjects experienced injection-site adverse reactions in the IM group after each dose (see section 5.1 for study description).
Splošna varnostna profila intramuskularne in subkutane aplikacije sta bila primerljiva, vendar so se v skupini, ki je cepivo prejela intramuskularno, neželeni učinki na mestu vboda po vsakem odmerku pojavili pri manjšem številu oseb (za opis študije glejte poglavje 5.1).
The general safety profiles of the SC and IM routes were otherwise comparable, but injection-site adverse reactions were significantly less frequent in the IM group (34%) compared with the SC group (64%).
Splošna varnostna profila sta bila pri subkutani in intramuskularni uporabi primerljiiva, vendar so bili neželeni učinki na mestu injiciranja pri intramuskularni uporabi (34 %) značilno manj pogosti kot pri subkutani (64 %).
The generation of foam must be avoided.
Izogibajte se nastanku pene.
The generation of foam should be avoided.
Izogibajte se nastanku pene.
The Genuair inhaler delivers the active ingredients directly into your lungs as you breathe in.
Inhalator Genuair vaš vdih uporablja za dovajanje zdravilnih učinkovin naravnost v pljuča.
The Genuair inhaler does not require cleaning but if necessary the outside of the mouthpiece may be wiped with a dry tissue or paper towel.
Inhalatorja Genuair ni treba čistiti, vendar pa lahko bolnik po potrebi obriše zunanjost ustnika s suhim robčkom ali papirnato brisačo.
The Genuair inhaler has a dose indicator to show approximately how many doses are left in the inhaler.
Inhalator Genuair je opremljen z indikatorjem odmerka, ki kaže približno število odmerkov, ki so še ostali v njem.
The Genuair inhaler is a multicomponent device made of plastic (polycarbonate, acrylonitrile- butadiene-styrene, polyoxymethylene, polyester-butylene-terephthalate, polypropylene, polystyrene) and stainless steel.
Inhalator Genuair sestavlja več kosov, izdelanih iz plastike (polikarbonata, akrilonitril-butadien-stirena, polioksimetilena, poliester-butilen-tereftalata, polipropilena, polistirena) in nerjavnega jekla.
The Genuair inhaler is a multicomponent device made of plastic (polycarbonate, acrylonitrile-butadiene- styrene, polyoxymethylene, polyester-butylene-terephthalate, polypropylene, polystyrene) and stainless steel.
Inhalator Genuair sestavlja več kosov, izdelanih iz plastike (polikarbonata, akrilonitril-butadien-stirena, polioksimetilena, poliester-butilen-tereftalata, polipropilena, polistirena) in nerjavnega jekla.
The Genuair inhaler is a white device fitted with an integral dose indicator and an orange dosage button.
Inhalator Genauir je bel pripomoček, ki ima vgrajen indikator odmerka ter oranžni gumb za odmerjanje.
The Genuair inhaler is equipped with a dose indicator to show you approximately how many doses are left in the inhaler.
Inhalator Genuair je opremljen z indikatorjem odmerka, ki vam kaže približno število odmerkov, ki so še ostali v njem.
The Genuair inhaler: instructions for use
Inhalator Genuair: Navodila za uporabo
The Genuair Inhaler: Instructions for use
Inhalator Genuair: Navodilo za uporabo
The geometric mean (CV%) Cmax and AUC(0-τ) exposures achieved for ponatinib 45 mg daily at steady state were 77 ng/mL (50%) and
Geometrično povprečje (CV %) Cmax in AUC(0-τ) izpostavljenosti, doseženo za ponatinib 45 mg na dan v stanju dinamičnega ravnovesja, je bilo 77 ng/ml (50 %) oz.
The geometric mean (standard deviation) steady state trough concentration (Cmin,ss) and AUCss was 4.2 (0.9) ng/mL and 3680 (1020) ng*hr/mL, respectively.
Geometrijska srednja vrednost (standardna deviacija) najnižje koncentracije v stanju dinamičnega ravnovesja (Cmin,ss) in AUCss je bila 4,2 (0,9) ng/ml oziroma 3680 (1020) ng* hr/ml.
The geometric mean AUCinf (CV%) for maraviroc was as follows: healthy volunteers (normal renal function) 1348.4 ng·h/mL (61%); severe renal function 4367.7 ng·h/mL (52%); ESRD (dosing after dialysis) 2677.4 ng·h/mL (40%); and ESRD (dosing before dialysis) 2805.5 ng·h/mL (45%).
Geometrična sredina AUCinf (KV %) za maravirok je bila: zdravi prostovoljci (normalno delovanje ledvic) 1348,4 ng·h/ml (61 %), huda motnja delovanja ledvic 4367,7 ng·h/ml (52 %), končna odpoved ledvic (odmerjanje po dializi) 2677,4 ng·h/ml (40 %) in končna odpoved ledvic (odmerjanje pred dializo) 2805,5 ng·h/ml (45 %).
The geometric mean clearance was estimated at 0.025 L/hr and increased with body size.
Povprečno geometrično izločanje je bilo ocenjeno na 0,25 l/uro in se je povečalo s telesno velikostjo.
The geometric mean Ctrough (CV%) values at Cycle 5 (pre-dose Cycle 6) were higher among the MabThera subcutaneous group than the MabThera intravenous group; 97.5 g/mL (42.6) versus 61.5 g/mL (63.9) respectively with a resulting adjusted geometric mean ratio [90% CI] of 1.53 [1.27-1.85].
Geometrične sredine Ctrough (KV %) v 5. ciklu (pred odmerkom 6. cikla) so bile višje v skupini, ki je zdravilo MabThera prejemala podkožno (97,5 µg/ml (42,6)), kot v skupini, ki je zdravilo MabThera prejemala intravensko (61,5 µg/ml (63,9)); prilagojeno razmerje geometričnih sredin [90-% IZ] je bilo 1,53 [1,27–1,85].
The geometric mean exposure to nintedanib was 33 % higher in Chinese, Taiwanese, and Indian patients while it was 22 % lower in Koreans compared to Caucasians (body weight corrected).
Geometrična srednja izpostavljenost nintedanibu je bila 33 % večja pri Kitajcih, Tajvancih in Indijcih, pri Korejcih pa 22 % manjša v primerjavi z belci (popravljena glede na telesno maso).
The geometric mean exposure to nintedanib was 33% higher in Chinese, Taiwanese, and Indian patients while it was 22% lower in Koreans compared to Caucasians (body weight corrected).
Geometrična srednja izpostavljenost nintedanibu je bila 33 % večja pri Kitajcih, Tajvancih in Indijcih, pri Korejcih pa 22 % manjša v primerjavi z belci (popravljena glede na telesno maso).
The geometric mean nevirapine Cmin,ss was 2,770 ng/ml.
Geometrična srednja vrednost nevirapinove Cmin,ss je bila 2.770 ng/ml.
The geometric mean of the C24h was 288 ng/mL in the non-smokers and 34.8 ng/mL in the smokers with a mean ratio of 12.1% (95% CI: 4.82 to 30.2, p = 0.0001).
Geometrijska sredina C24h je bila 288 ng/ml pri nekadilcih in 34,8 ng/ml pri kadilcih s povprečnim razmerjem 12,1 % (95-% interval zaupanja: 4,82 do 30,2; p = 0,0001).
The geometric mean oral clearance and apparent volume of distribution were 38 L/h and 160 L, respectively.
Geometrična srednja vrednost očistka po peroralni uporabi in navidezni volumen porazdelitve sta znašala 38 L/h oziroma 160 L.
The geometric mean ratio and 90% CI for the primary PK endpoints were 1.01 [90%CI: 0.959-1.07] and 1.02 [90%CI: 0.956-1.10] for AUC0-21 days and Cmax, respectively.
Geometrijsko povprečno razmerje in 90-% interval zaupanja za primarno farmakokinetično končno točko AUC0-21. dan je bil 1,01 [90-% interval zaupanja: 0,959–1,07], za cmax pa 1,02 [90-% interval zaupanja: 0,956–1,10].
The geometric mean terminal carbovir-TP intracellular half-life at steady-state was 20.6 hours, compared to the geometric mean abacavir plasma half-life of 2.6 hours.
Geometrični srednji končni znotrajcelični razpolovni čas karbovir trifosfata je znašal v stanju dinamičnega ravnovesja 20,6 ure, v primerjavi z geometričnim srednjim razpolovnim časom abakavirja, ki je bil 2,6 ure.
The geometric mean titers (GMTs) following the second dose of ProQuad increased approximately 2 fold each for measles, mumps, and rubella, and approximately 41 fold for varicella (for safety information, see section 4.8).
Geometrična povprečja titrov (GMT = geometric mean titers) protiteles proti ošpicam, mumpsu in rdečkam so se po drugem odmerku cepiva ProQuad približno podvojila, proti noricam pa so se povečala za približno 41-krat (za podatke o varnosti glejte poglavje 4.8).
The Geometric Mean Titers (GMTs) were somewhat lower than reported in non-HIV infected subjects of the same age in other studies.
Geometrična sredina titrov (GMT) je bila nekoliko nižja kot pri enako starih, s HIV neokuženih osebah v drugih študijah.
The GLA mutations are also accessible by health care providers at www.galafoldamenabilitytable.com:
Mutacije gena GLA so izvajalcem zdravstvenih dejavnosti dostopne tudi na spletnem naslovu www.galafoldamenabilitytable.com:
The glass cartridge is irreversibly integrated in a transparent container and attached to a plastic mechanism by a threaded rod at one extremity.
Stekleni vložek je neločljivo vgrajen v prozoren vsebnik; na eni strani ima nameščen plastičen mehanizem z nazobčanim potisnikom.
The glass should be rinsed with a further half glass of water (120 ml) and the contents drunk.
Kozarec morajo nato splakniti z dodatnega pol kozarca vode (120 ml) in to vodo popiti.
The glass should be rinsed with half a glass of water, which should also be drunk.
Kozarec splaknite z vodo in vsebino popijte.
The glass syringe contains sodium chloride 9 mg/ml (0.9%) solution for injection.
Steklena injekcijska brizga vsebuje 9 mg/ml (0,9 %) raztopino natrijevega klorida za injiciranje.
The glass vials are supplied in a carton containing 5 vials.
Steklene viale so na voljo v škatlah s 5 vialami.
The GLP­1 receptor is the target for native GLP­1, an endogenous incretin hormone that potentiates glucose­dependent insulin secretion from the pancreatic beta cells.
Receptor za GLP-1 je tarča naravnega GLP-1: to je endogen inkretinski hormon, ki od glukoze odvisno poveča izločanje insulina iz celic beta trebušne slinavke.
The glucose excursion (AUC 0-6h) was 641 mg.h.dl-1 for insulin glulisine and 801 mg.h.dl-1 for regular human insulin.
Ekskurz glukoze (AUC 0–6h) je bil pri insulinu glulisin 641 mg.h.dl-1 in pri navadnem humanem insulinu 801 mg.h.dl-1.
The glucose excursion (AUC0-6h) was 641 mg.h.dl-1 for insulin glulisine and 801 mg.h.dl-1 for regular human insulin.
Ekskurz glukoze (AUC 0–6h) je bil pri insulinu glulisin 641 mg.h.dl-1 in pri navadnem humanem insulinu 801 mg.h.dl-1.
The glucuronidation resulted in the formation of the 1-O-acylglucuronide metabolite of telmisartan.
Glukuronizacija povzroči nastajanje 1-O-acil- glukuronidnega presnovka telmisartana.
The GMTs to HPV Types 6, 11, 16, 18 were higher than in the population who had not previously received qHPV vaccine in other studies whereas the GMTs to HPV Types 31, 33, 45, 52 and 58 were lower.
GMT za tipe HPV 6, 11, 16 in 18 so bili višji kot v populaciji, ki predhodno ni prejela qHPV cepiva v drugih študijah, GMT za tipe HPV 31, 33, 45, 52 in 58 pa so bili nižji.
The goal is to gradually create bending opposite to the patient’s penile curvature, with stretching to the point of moderate resistance.
Cilj je, da se z raztezanjem do točke zmernega odpora postopno ustvari upognjenost, ki je nasprotna bolnikovi ukrivljenosti penisa.
The GOG-0218 study was a phase III multicentre, randomised, double-blind, placebo-controlled, three arm study evaluating the effect of adding Avastin to an approved chemotherapy regimen (carboplatin and paclitaxel) in patients with advanced (FIGO stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube or primary peritoneal cancer.
Študija GOG-0218 je bila multicentrična, randomizirana, dvojno slepa, s placebom primerjana študija faze III, ki je vključevala tri skupine, kjer so ocenjevali vpliv dodajanja zdravila Avastin k odobrenemu režimu kemoterapije (karboplatin in paklitaksel) pri bolnicah z napredovalim (FIGO klasifikacija: stadij III B, III C in IV) epitelijskim rakom jajčnikov, karcinomom jajcevodov in primarnim peritonealnim karcinomom.
The GONAL-f and GnRH agonist are then both given until your follicles develop as desired.
Nato se dajeta zdravilo GONAL-f in agonist GnRH do želenega razvoja foliklov.
the good condition of the material should be checked before use
pred uporabo preverite, ali je oprema v dobrem stanju
The Grade 3 or Grade 4 adverse reactions reported for  5% of patients were thrombocytopenia (25.4%), anaemia (12.3%), neutropenia (11.5%), alanine aminotransferase increased (10.2%), diarrhoea (9.1%), rash (6.1%), lipase increased (5.2%) and aspartate aminotransferase increased (5.0%).
Neželeni učinki stopnje 3 ali 4, o katerih so poročali pri  5 % bolnikov, so bili trombocitopenija (25,4 %), anemija (12,3 %), nevtropenija (11,5 %), povečane vrednosti alanin aminotransferaze (10,2 %), diareja (9,1 %), izpuščaj (6,1 %), povečane vrednosti lipaze (5,2 %) in povečane vrednosti aspartat aminotransferaze (5,0 %).
The grades follow CTCAE Version 3.0.
Stopnje so usklajene s CTCAE Verzija 3.0.
The graduated pre-filled syringe allows for doses between 20 and 100 mg.
Napolnjena odmerna injekcijska brizga omogoča odmerke od 20 do 100 mg.